ImmunityBio (NASDAQ: IBRX) CAO RSUs vest and shares withheld for taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ImmunityBio, Inc. Chief Accounting Officer Regan J. Lauer reported vesting of 4,065 restricted stock units (RSUs) on February 22, 2026. Each RSU converts into one share of common stock, so 4,065 shares were acquired at a stated price of $0.00 per share.
To satisfy tax obligations from this vesting, 1,673 common shares were disposed of at $8.70 per share through share withholding, rather than an open-market sale. After these transactions, Lauer directly owns 115,875 shares of ImmunityBio common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
4,065 shares exercised/converted
Mixed
3 txns
Insider
LAUER REGAN J
Role
Chief Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 4,065 | $0.00 | -- |
| Exercise | Common Stock | 4,065 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,673 | $8.70 | $15K |
Holdings After Transaction:
Restricted Stock Units — 4,065 shares (Direct);
Common Stock — 117,548 shares (Direct)
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.
FAQ
What insider transactions did ImmunityBio (IBRX) report for Regan J. Lauer?
ImmunityBio reported that Chief Accounting Officer Regan J. Lauer had 4,065 restricted stock units vest into common shares, then 1,673 of those shares were withheld to cover tax obligations, leaving Lauer with direct ownership of 115,875 ImmunityBio common shares.
Were the ImmunityBio (IBRX) insider transactions open-market buys or sales?
The transactions were not open-market trades. Lauer’s 4,065 shares were acquired through RSU vesting (code M), and 1,673 shares were disposed of via share withholding (code F) to pay tax liabilities associated with the vesting, rather than through open-market purchases or sales.
What do the restricted stock units (RSUs) represent for ImmunityBio (IBRX)?
Each ImmunityBio restricted stock unit represents a contingent right to receive one share of ImmunityBio common stock. When the RSUs vest, as they did on February 22, 2026 for 4,065 units, they automatically convert into an equal number of common shares for the reporting person.
What is the vesting schedule for the ImmunityBio (IBRX) RSU award?
The RSU award vests over three years from a February 22, 2024 vesting commencement date. 33.33% vests in equal annual installments on each of the first and second anniversaries, and 33.34% vests on the third anniversary, subject to continued service as a Service Provider.